诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

美国阵亡战士纪念日休市 05-22 16:00:00 EDT

44.96

+0.57

+1.28%

盘后44.85

-0.11-0.24%

19:59 EDT

最高45.18	最低44.47	成交量1,079万
今开44.61	昨收44.39	日振幅1.61%
总市值1,996亿	流通市值1,433亿	总股本44.39亿
成交额4.83亿	换手率0.34%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":44.96,"timestamp":1779480000000,"preClose":44.39,"halted":0,"volume":10790951,"hourTrading":{"tag":"盘后","latestPrice":44.85,"preClose":44.96,"latestTime":"19:59 EDT","volume":449358,"amount":20203358.3503,"timestamp":1779494394568,"change":-0.11,"changeRate":-0.002447,"amplitude":0.002891},"delay":0,"changeRate":0.012840729894120304,"floatShares":3187922885,"shares":4439052849,"eps":4.228648,"marketStatus":"美国阵亡战士纪念日休市","change":0.57,"latestTime":"05-22 16:00:00 EDT","open":44.61,"high":45.18,"low":44.465,"amount":483239936.04396,"amplitude":0.016107,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.228648,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":44.39,"dividendRate":0.038299,"preHourTrading":{"tag":"盘前","latestPrice":44.61,"preClose":44.39,"latestTime":"09:29 EDT","volume":395576,"amount":17510974.65928,"timestamp":1779456599999,"change":0.22,"changeRate":0.004956,"amplitude":0.024792},"postHourTrading":{"tag":"盘后","latestPrice":44.85,"preClose":44.96,"latestTime":"19:59 EDT","volume":449358,"amount":20203358.3503,"timestamp":1779494394568,"change":-0.11,"changeRate":-0.002447,"amplitude":0.002891},"volumeRatio":0.8446040334914887,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1787284800000,"strike":"45.0","timestamp":1779463973681,"price":3.77,"volume":1350,"amount":508950,"type":"-"}]},"impliedVol":0.3339,"impliedVolPercentile":0.0279},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2637434972","title":"诺和诺德高剂量Wegovy单剂量注射笔获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637434972","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637434972?lang=zh_cn&edition=full","pubTime":"2026-05-23 03:00","pubTimestamp":1779476452,"startTime":"0","endTime":"0","summary":"诺和诺德于5月22日宣布，欧洲药品管理局人用药品委员会已采纳积极意见，推荐批准Wegovy 7.2 mg单剂量注射笔在欧盟上市，用于成人肥胖症患者的体重管理。此次获批的单剂量注射笔将三针合为一体，大幅提升了用药便利性。　　诺和诺德预计将于2026年第三季度在欧盟正式推出Wegovy 7.2 mg单剂量注射笔。该产品已在美国以Wegovy HD品牌名上市销售。受此消息提振，诺和诺德股价当日上涨约2.4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhtw8043890.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["BK4532","LU1093756168.USD","NVO","BK4588","BK4585","BK4007","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","NVOX","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334393","title":"诺和诺德(NVO)Wegovy获欧洲背书 GLP1赛道竞争持续升温","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334393","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334393?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:58","pubTimestamp":1779461893,"startTime":"0","endTime":"0","summary":"在此之前，Wegovy的每周皮下注射剂型已在欧洲获批上市，用于体重管理。早在去年12月，该药物已获美国FDA批准，诺和诺德也于今年正式将其推向美国口服减肥药市场。除诺和诺德外，药企礼来的每日口服减重疗法Foundayo也已登陆美国市场，两大药企形成正面竞争格局。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4599","NVOH","NVOX","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4007","BK4532","NVO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637336886","title":"减重神药或能抑制癌症发展，诺和诺德、礼来迎重磅利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2637336886","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637336886?lang=zh_cn&edition=full","pubTime":"2026-05-22 06:52","pubTimestamp":1779403947,"startTime":"0","endTime":"0","summary":"四项覆盖数十万患者的研究显示，Ozempic（司美格鲁肽）、Mounjaro（替尔泊肽）等明星减肥药或能抑制癌症发展——肺癌进展率近乎减半，乳腺癌五年生存率从89.5%跃升至95%以上。研究人员指出，现有证据仅显示关联性，而非因果关系。若抗癌效益最终获证，将再度重塑诺和诺德与礼来的医学与商业版图。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3772873","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0079474960.USD","LU2471134879.HKD","LU2896262040.SGD","LU0823434740.USD","SG9999015945.SGD","IE0004445239.USD","IE00BKPKM429.USD","LU2361045086.USD","LU1974910355.USD","SG9999014880.SGD","LU1868837300.USD","IE0005OL40V9.USD","IE00BK4W5M84.HKD","LU2211815571.USD","LU1720051017.SGD","LU0256863902.USD","LU2236285917.USD","IE0002141913.USD","LU2552382215.SGD","LU0133085943.USD","LU0787776722.HKD","IE00BJLML261.HKD","IE00B4JS1V06.HKD","LU0353189763.USD","LU0385154629.USD","LU0823434583.USD","LU0471298777.SGD","SGXZ51526630.SGD","IE00BK4W5L77.USD","IE00BKVL7J92.USD","NVOX","LU1917777945.USD","LU0820562030.AUD","LU1868836591.USD","LU2361044865.SGD","LU2237443549.SGD","LU2417539215.USD","LU0097036916.USD","LU0471298694.HKD","LU0882574055.USD","LU2089984988.USD","SGXZ31699556.SGD","LU1548497426.USD","LU2750360641.GBP","BK4581","GB00BDT5M118.USD","IE00BFSS8Q28.SGD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU0466842654.USD","LU1093756168.USD","LU2237443622.USD","SG9999013999.USD","LU0198837287.USD","SGXZ57979304.SGD","LU1804176565.USD","LU2602419157.SGD","SGXZ81514606.USD","LU1868836914.USD","IE00B2B36J28.USD","LU2168564222.USD","LU2108987350.USD","SG9999001176.USD","IE00BZ1G4Q59.USD","SG9999014906.USD","ELIL","LU0417517546.SGD","IE00B7KXQ091.USD","LU0203201768.USD","LU1145028129.USD","LU2357305700.SGD","LU1061106388.HKD","LU2462157665.USD","ELIS","LLII","LU1232071149.USD","LU2106854487.HKD","LU0114720955.EUR","LU1814569148.SGD","LU0708995401.HKD","IE00BWXC8680.SGD","NVOH","LU0106261372.USD","SG9999014898.SGD","IE00B1XK9C88.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","SG9999014914.USD","BK4533","LU0238689110.USD","LU0266013472.USD","LU0323591593.USD","LU2750360997.AUD","LU0058720904.USD","LU0203202063.USD","LU0823416689.USD","LU1623119135.USD","LU1267930730.SGD","LU1069344957.HKD","LU2746668974.SGD","LU2089284900.SGD","LU2023250504.SGD","BK4585","LU1629891620.HKD","IE0004445015.USD","LU0964807845.USD","LU1720051108.HKD","LU2063271972.USD","IE00BJJMRX11.SGD","SG9999015952.SGD","BK4534","LU2491050154.USD","LU1127390331.HKD","SG9999015978.USD","LU0320765059.SGD","SG9999001176.SGD","LU0061475181.USD","LU0289739699.SGD","LU0354030438.USD","BK4588","LU0354030511.USD","IE00B1BXHZ80.USD","LU0109394709.USD","LU0234572021.USD","LU2746668461.USD","LU2471134523.USD","LU0689472784.USD","IE00B775H168.HKD","LU2028103732.USD","LU2168564065.EUR","LU2471134952.CNY","LU1551013425.SGD","LU0096364046.USD","LU0672654240.SGD","LU2168564149.EUR","IE0001KFT4U8.USD","LU2237443382.USD","LU2491050071.SGD","LU1551013342.USD","SG9999017495.SGD","LLYX","LU0640476718.USD","LU2237443895.HKD","SG9999018865.SGD","LU2360106947.USD","BK4516","LU2112291526.USD","LU0158827948.USD","IE00BJT1NW94.SGD","LU1983299246.USD","LU2361044949.HKD","LU0316494557.USD","LU2213496289.HKD","LU2491049909.HKD","LU2756315318.SGD","LU0820561818.USD","LU1064131342.USD","LU2168564495.EUR","LU1989771016.USD","LU0109391861.USD","LU2324357040.USD","LU0786609619.USD","LU2265009873.SGD","LU1093756325.SGD","LU0154236417.USD","SGXZ99366536.SGD","LU1712237335.SGD","LU0432979614.USD","LU0353189680.USD","LU2023250330.USD","LU0006306889.USD","LU2237443978.SGD","SG9999018857.SGD","IE00B4R5TH58.HKD","LU0158827781.USD","LU1057294990.SGD","LU2237443465.HKD","LU2461242641.AUD","LU1023059063.AUD","LLY","BK4007","BK4532","BK4599","LU1868837136.USD","LU0889565916.HKD","LU0683600562.USD","IE00BKDWB100.SGD","LU0256863811.USD","SG9999015986.USD","LU0225283273.USD","LU1868836757.USD","IE00BFSS7M15.SGD","NVO","LU0943347566.SGD","LU1291159041.SGD","LU2168563687.JPY","LU2111349929.HKD","LU2456880835.USD","IE0009355771.USD","LLYZ","LU2264538146.SGD","LU2089283258.USD","LU2552382132.HKD","LU1988902786.USD","LU1323610961.USD","LU2237438978.USD","IE00BJJMRY28.SGD","LU0210536198.USD","LU1035775433.USD","LU0882574139.USD","LU1280957306.USD","LU2468319806.SGD","IE00BN29S564.USD","LU0094547139.USD","LU2756315664.SGD","LU2023251221.USD","LU0820561909.HKD","LU2552382058.USD","LU1366192091.USD","LU2271345857.HKD","LU2087625088.SGD","LU2471134796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636028536","title":"诺和诺德计划推动Wegovy口服减肥药登陆美国以外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2636028536","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636028536?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:40","pubTimestamp":1779090023,"startTime":"0","endTime":"0","summary":"诺和诺德透露，随着减肥药市场的全球争夺战愈演愈烈，公司正准备全力推动旗下Wegovy口服减肥药登陆美国以外市场。　　目前诺和诺德及其主要竞争对手礼来制药，过半以上销售额都来自美国市场。　　拉森并未透露Wegovy口服药首批出海上市的具体国家，只表示药企会依照市场潜力进行布局，同时会考量当地肥胖症患者需求、医生专业素养以及远程医疗合作资源等条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-18/doc-inhyiewm2822146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["NVO","NVOH","BK4585","LU0154236417.USD","BK4588","LU1093756325.SGD","LU1093756168.USD","BK4599","IE00BKVL7J92.USD","NVOX","IE00BZ1G4Q59.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635842857","title":"减重赛道激战正酣：跨国巨头齐亮剑，竞争升维至全病程管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635842857","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635842857?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:54","pubTimestamp":1778673240,"startTime":"0","endTime":"0","summary":"在2026年世界防治肥胖日到来、“体重管理年”行动收官的关键节点，全球减重药物市场的火药味达到了新的浓度。从伊斯坦布尔第33届欧洲肥胖大会（ECO），到国内学术峰会，诺和诺德、礼来以及辉瑞/先为达等跨国药企与本土创新力量，不约而同地选择在这一时间窗口密集“亮剑”，发布了各自在减重领域的最新重磅数据。这并非巧合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133736129640.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736129640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0868494617.USD","SGXZ57979304.SGD","IE00BLSP4452.SGD","BK4534","LU1093756325.SGD","IE00BBT3K403.USD","BK4568","BK4588","NVOH","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU0985481810.HKD","BK4532","LU0154236417.USD","LU1066053197.SGD","LU0456855351.SGD","LU0321505439.SGD","SG9999001176.SGD","IE0002270589.USD","LU0225771236.USD","IE00BKVL7J92.USD","BK4581","LU1894683348.USD","SG9999001176.USD","BK4592","BK4550","SG9999002232.USD","BK4585","IE00B19Z3581.USD","LU1894683264.USD","BK4533","IE000M9KFDE8.USD","LU0234572021.USD","LU1057294990.SGD","LU0306807586.USD","ECO","LU1023059063.AUD","LU0225284248.USD","LU1883839398.USD","PFE","NVO","BK4144","LU0058720904.USD","BK4007","SG9999003800.SGD","IE00BLSP4239.USD","SG9999011175.SGD","NVOX","IE00B19Z3B42.SGD","LU0997586861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137321098","title":"市场聚焦：游戏驿站、Venture Global、温蒂汉堡、Hims & Hers等个股动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1137321098","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137321098?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:09","pubTimestamp":1778587787,"startTime":"0","endTime":"0","summary":"游戏驿站 ：这家视频游戏零售商的董事会拒绝了eBay主动提出的560亿美元收购要约，其股价在盘前交易中应声下跌。Venture Global ：这家液化天然气出口商报告第一季度营收和利润大幅增长后，其股价在盘前交易中上涨了9%。Hims & Hers ：这家远程医疗平台的股价在盘前下跌了15%，原因是该公司表示，其调整减肥产品线的举措推高了成本。ZoomInfo Technologies Inc. ：这家市场情报公司的股价在周一晚些时候下调全年业绩指引后大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1ee3020066801ecc9807d71c3848eaf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NVOX","VG","BK4599","BK4077","BK4532","GTM","GMEY","GPRO","WEN","BK4213","IGME","IE00BKVL7J92.USD","UA","BK4577","BAYRY","GMEU","IE00BZ1G4Q59.USD","NVOH","HMYY","BK4585","BK4196","BK4007","BK4202","BK4209","HIMZ","LU1093756325.SGD","NVO","BK4588","BK4076","HIYY","LU1093756168.USD","GME","HIMY","BK4078","LU0154236417.USD","HIMS","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110023794","title":"关注焦点：Venture Global、Hims & Hers、GoPro等个股动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1110023794","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110023794?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577489,"startTime":"0","endTime":"0","summary":"液化天然气出口商Venture Global Inc. 将于今日早间公布财报。由于霍尔木兹海峡关闭，该公司有望从中受益，其业绩或将揭示当前市场需求的实际强度。该股在盘前交易中已出现上涨。远程医疗平台Hims & Hers Health Inc. 的股价在盘前重挫逾15%。此前，该公司表示，其对减肥产品线的调整重组导致成本上升。运动品牌Under Armour 和On Holding AG 预计将于今日发布财报。市场情报公司ZoomInfo Technologies Inc. 股价暴跌。该公司于周一晚间下调了其全年业绩指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4146","LU0154236417.USD","LU0289961442.SGD","HIMY","LU0289739343.SGD","LU1804176565.USD","LU1093756168.USD","BK4196","BK4213","BK4585","NVO","BK4599","BK4077","HIMS","BK4202","HMYY","LU0069063385.USD","IE00BZ1G4Q59.USD","BK4007","NVOH","HIMZ","LU0511384066.AUD","NVOX","LU0472753341.HKD","BK4588","ONON","BK4532","BK4023","BK4078","HIYY","BAYRY","GPRO","VG","GTM","IE00BKVL7J92.USD","LU2265009873.SGD","UA","BK4547","LU1093756325.SGD","LU0057025933.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634260647","title":"扎克伯格投资生物药企拿下诺和诺德细胞疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2634260647","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634260647?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:42","pubTimestamp":1778568166,"startTime":"0","endTime":"0","summary":"细胞疗法等先进生物技术力量正在向新兴AI医疗公司转移。当地时间5月11日，一家成立仅两年多的生物技术公司CellularIntelligence宣布收购丹麦制药巨头诺和诺德的一款在研的帕金森细胞疗法。CellularIntelligence是由硅谷巨头Meta公司创始人扎克伯格投资的一家由人工智能驱动的细胞疗法公司，在早期融资中曾获得扎克伯格等投资人超过6000万美元的资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734394252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734394252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4599","IE00BKVL7J92.USD","LU1093756325.SGD","BK4532","BK4588","LU1093756168.USD","NVOX","BK4007","BK4585","NVO","META","LU0154236417.USD","IE00BZ1G4Q59.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633045582","title":"诺和诺德(NVO.US)在印度降价后 减肥药销量4月激增40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633045582","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633045582?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:52","pubTimestamp":1778241130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德上月印度糖尿病及减肥药物销量激增40%，起因是大幅降价显著提振了其品牌药物需求——尽管仿制GLP-1疗法正大量涌入市场。自4月1日起，诺和诺德将两种药物起始剂量价格分别下调36%和48%，使价格降至5660卢比。尽管礼来公司在经历早期挫折后仍保持印度GLP-1药物销量领先地位，但这些低价仿制药的销量推动4月市场环比激增56%，总量达41.4万剂。截至目前，诺和诺德和礼来公司代表未对此事作出回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4599","IE00BZ1G4Q59.USD","NVOX","BK4532","LU1093756325.SGD","NVOH","NVO","BK4585","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2633410627","title":"跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手","url":"https://stock-news.laohu8.com/highlight/detail?id=2633410627","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633410627?lang=zh_cn&edition=full","pubTime":"2026-05-08 07:52","pubTimestamp":1778197920,"startTime":"0","endTime":"0","summary":"【跨国药企开门红 巨头领跑减重赛道 “王牌”产品成增长胜负手】有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。纵观财报数据，一个清晰的信号也正在浮现：在专利悬崖、政策博弈与市场竞争的多重挑战中，如何深度挖掘并战略性运营核心大单品，已从“增长选择”演变为“生存命题”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083730569459.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083730569459.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001440.SGD","LU0130517989.USD","LU0106261372.USD","LU2089984988.USD","LU0965509283.SGD","LU0208291251.USD","LU2125154778.USD","LU1066051811.HKD","NVOX","SG9999015341.SGD","LU0238689110.USD","LU0289739699.SGD","LU1571399168.USD","LU2461242641.AUD","IE00BFTCPJ56.SGD","LU1162221912.USD","NVOH","IE00BZ1G4Q59.USD","LU0234572021.USD","IE00B2B36J28.USD","BK4585","LU0098860793.USD","SG9999014575.USD","LU2023250504.SGD","IE00B4R5TH58.HKD","LU1066051498.USD","BK4534","LU1023059063.AUD","LU1430594728.SGD","LU2106854487.HKD","SG9999001176.SGD","LU1069347547.HKD","LU0154236417.USD","LU2361044949.HKD","LU2360032135.SGD","LU0203345920.USD","SG9999014559.SGD","LU2361044865.SGD","LU0965508806.USD","LU1037948897.HKD","LU2491049909.HKD","LU0122379950.USD","SGXZ57979304.SGD","LU0320765489.SGD","LU0211331839.USD","IE00BLSP4239.USD","IE0009355771.USD","LU1093756168.USD","LU1116320737.USD","LU0985320562.USD","SNY","LU1941712348.USD","LU0070302665.USD","LU0859254822.USD","LU1066053197.SGD","IE00BKVL7J92.USD","LU1989771016.USD","IE00BJT1NW94.SGD","LU0006306889.USD","IE00BJJMRZ35.SGD","LU1116320901.HKD","LU0861579265.USD","BK4599","IE0002141913.USD","LU2125154935.USD","IE00BN8TJ469.HKD","LU0130102774.USD","LU1585245621.USD","LU0965509010.AUD","BK4550","NVO","LU1093756325.SGD","IE00BBT3K403.USD","SG9999013999.USD","LU0266013472.USD","BK4559","LU1934455277.USD","IE000M9KFDE8.USD","LU0980610538.SGD","SG9999014567.USD","BK4532","LU0320765646.SGD","LU0058720904.USD","LU0432979614.USD","LU1989772923.USD","LU0265550946.USD","LU1929549753.HKD","LU1035773651.USD","LU0265550359.USD","LU1061106388.HKD","LU1291159041.SGD","LU0965509101.SGD","LU2324357040.USD","MRK","IE00BLSP4452.SGD","LU1057294990.SGD","LU2361045086.USD","LU1699723380.USD","LU1201861249.SGD","LU1983299246.USD","LU2357627491.SGD","SG9999015358.SGD","LU2112291526.USD","SG9999001176.USD","BK4007","IE00B1BXHZ80.USD","SG9999002224.SGD","LU0868494708.USD","LLY","LU0868494617.USD","BK4533","LU2491050154.USD","SG9999002232.USD","BK4516","LU2468319806.SGD","LU1934455194.USD","LU1066051225.USD","LU2023250843.SGD","SG9999014542.SGD","LU1941712264.USD","LU0203347892.USD","IE00BSNM7G36.USD","LU0942090050.USD","LU1037948541.HKD","LU1917777945.USD","LU1934455863.HKD","BK4588","LU1974910355.USD","LU1989772840.SGD","LU2491050071.SGD","LU0648001328.SGD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年第一季度，全球制药巨头的业绩版图再度刷新。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0130517989.USD","EUO","LU0965508806.USD","LU1989772840.SGD","BK4534","LU0122379950.USD","LU2361044865.SGD","BK4588","LU0648001328.SGD","LU0477156953.USD","LU2360032135.SGD","LU2491050154.USD","LU2089984988.USD","LU0868494708.USD","IE00BJJMRZ35.SGD","BK4550","IE00BBT3K403.USD","LU0266013472.USD","LU1585245621.USD","LU0265550359.USD","LU1571399168.USD","LU0861579265.USD","SG9999013999.USD","LU0203345920.USD","LU0098860793.USD","LU1941712264.USD","LU1989771016.USD","LU2361044949.HKD","IE00B2B36J28.USD","LU0234572021.USD","SG9999001176.USD","BMY","LU0868494617.USD","NVS","LU0203347892.USD","LU1066051811.HKD","BK4585","SGXZ57979304.SGD","LU2361045086.USD","SG9999002232.USD","IE00BN8TJ469.HKD","LU2324357040.USD","LU2023250504.SGD","IE000M9KFDE8.USD","LU1430594728.SGD","LU1934455194.USD","LU1934455863.HKD","IE00BLSP4239.USD","LU1699723380.USD","LU2461242641.AUD","SG9999002224.SGD","LU0965509010.AUD","LU0289739699.SGD","LU0965509283.SGD","LU0238689110.USD","LU0965509101.SGD","IE00BFTCPJ56.SGD","LU0980610538.SGD","LU1917777945.USD","MRK","BK4007","LU1037948897.HKD","IE0009355771.USD","LU2357627491.SGD","IE00B4R5TH58.HKD","IE00B1BXHZ80.USD","NVO","LU0211331839.USD","SNY","LU0106261372.USD","LU0265550946.USD","LU1093756168.USD","IE00BKVL7J92.USD","LU1069347547.HKD","MEURmain","FXE","BK4516","LU1093756325.SGD","AZN","LU1037948541.HKD","IE00BZ1G4Q59.USD","LU1061106388.HKD","LU1201861249.SGD","LU1974910355.USD","LU1023059063.AUD","LU1066051225.USD","LU2491049909.HKD","IE00BSNM7G36.USD","IE0002141913.USD","LU2125154778.USD","SG9999014575.USD","LU0130102774.USD","LU2112291526.USD","SG9999001176.SGD","BK4599","IE00BLSP4452.SGD","LU1983299246.USD","LU0320765489.SGD","LU1116320901.HKD","LU2106854487.HKD","BK4559","LU2023250843.SGD","BK4533","LU1162221912.USD","LU1929549753.HKD","IE00BJT1NW94.SGD","LU1035773651.USD","SG9999014567.USD","SG9999015341.SGD","LU0058720904.USD","LU1116320737.USD","SG9999014559.SGD","LLY","NVOH","LU1057294990.SGD","NVOX","LU1066051498.USD","SG9999001440.SGD","LU2491050071.SGD","EURmain","LU1934455277.USD","LU0432979614.USD","LU0985320562.USD","LU1066053197.SGD","LU1291159041.SGD","LU2468319806.SGD","LU0154236417.USD","LU0006306889.USD","LU2125154935.USD","LU0320765646.SGD","LU0942090050.USD","SG9999014542.SGD","LU0208291251.USD","LU1989772923.USD","LU1941712348.USD","SG9999015358.SGD","LU0070302665.USD","BK4532","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633192586","title":"丹斯克银行：将诺和诺德目标价上调至320丹麦克朗","url":"https://stock-news.laohu8.com/highlight/detail?id=2633192586","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633192586?lang=zh_cn&edition=full","pubTime":"2026-05-07 14:17","pubTimestamp":1778134622,"startTime":"0","endTime":"0","summary":"丹斯克银行将诺和诺德目标价从300丹麦克朗上调至320丹麦克朗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260507/32205968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4588","NVOH","IE00BKVL7J92.USD","BK4585","NVO","NVOX","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633188951","title":"开门红！诺和诺德司美格鲁肽大卖，减重口服剂型成新增长引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2633188951","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633188951?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:01","pubTimestamp":1778058060,"startTime":"0","endTime":"0","summary":"5月6日，丹麦制药巨头诺和诺德发布了2026年第一季度财报。财报显示，公司第一季度销售额达到968.23亿丹麦克朗，以丹麦克朗计算同比增长24%，以固定汇率计算同比增长32%。在明星产品司美格鲁肽家族的全面拉动下，诺和诺德交出了一份大幅超出市场预期的成绩单。一季度，司美格鲁肽全线维持增长态势，合计销售额突破528.88亿丹麦克朗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605063728689756.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605063728689756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","NVOH","NVO","BK4599","IE00BKVL7J92.USD","NVOX","BK4532","BK4588","BK4007","BK4585","IE00BZ1G4Q59.USD","LU1093756168.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168354324","title":"异动解读 | 诺和诺德盘前大涨7.49%，Q1业绩远超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1168354324","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168354324?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:10","pubTimestamp":1778055005,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘前股价大幅上涨7.49%，引起了市场的广泛关注。同时，公司的明星减肥药物Wegovy销售额为182.35亿丹麦克朗，也超出市场预估。基于此，诺和诺德上调了2026年的业绩预期，预计全年调整后销售额同比下降幅度收窄至4%至12%，此前预期为同比下降5%至13%，这增强了投资者对公司未来发展的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0b75b17847cc909466b55538fee5d425","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633902964","title":"诺和诺德：一季度减重口服剂型处方量超130万张","url":"https://stock-news.laohu8.com/highlight/detail?id=2633902964","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633902964?lang=zh_cn&edition=full","pubTime":"2026-05-06 15:45","pubTimestamp":1778053500,"startTime":"0","endTime":"0","summary":"人民财讯5月6日电，诺和诺德发布的2026年一季度财报显示，减重版司美格鲁肽口服片剂Wegovy?片剂单季处方量超过130万张，累计总处方量超过200万张，贡献了22.56亿丹麦克朗的销售额。财报披露，3月份国家药品监督管理局正式批准了依柯胰岛素司美格鲁肽注射液（商品名：诺和杰?）在中国的上市申请，它是全球首个且目前唯一获批的基础胰岛素/GLP-1RA周制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605063728586895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4007","LU0154236417.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU1093756168.USD","BK4599","NVOH","IE00BZ1G4Q59.USD","NVOX","BK4532","BK4588","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633438901","title":"诺和诺德欧股上涨7.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633438901","media":"东方财富Choice...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633438901?lang=zh_cn&edition=full","pubTime":"2026-05-06 15:07","pubTimestamp":1778051243,"startTime":"0","endTime":"0","summary":"【诺和诺德欧股上涨7.5%】诺和诺德公司上调销售指引后，欧股上涨7.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605063728567342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4532","LU1093756168.USD","NVO","BK4588","BK4585","BK4007","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","NVOX","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146402532","title":"异动解读 | 诺和诺德夜盘大涨5.15%，Q1业绩超预期叠加口服药管线利好提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1146402532","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146402532?lang=zh_cn&edition=full","pubTime":"2026-05-06 14:35","pubTimestamp":1778049334,"startTime":"0","endTime":"0","summary":"诺和诺德今日夜盘股价大幅上涨5.15%，引起了市场的广泛关注。基于此，诺和诺德上调了2026年的业绩预期，预计全年调整后销售额同比下降幅度收窄至4%至12%，此前预期为同比下降5%至13%。同时，公司的口服GLP-1药物在针对青少年的临床试验中达到了主要终点，计划于下半年申报新适应症，强化了市场对公司未来增长潜力的信心。另有研究显示，诺和诺德的GLP-1药物司美格鲁肽在治疗酒精使用障碍方面展现出潜力，为药物开辟了新的应用前景。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0b75b17847cc909466b55538fee5d425","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633590349","title":"诺和诺德Q1净利润及明星减肥药销量均高于预期，上调2026年业绩展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2633590349","media":"智通财经APP","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633590349?lang=zh_cn&edition=full","pubTime":"2026-05-06 13:31","pubTimestamp":1778045486,"startTime":"0","endTime":"0","summary":"预计全球GLP-1市场将持续扩张。","market":"us","thumbnail":"https://static.tigerbbs.com/257a3e30cbff798890dbfcb71b0e7f1e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/257a3e30cbff798890dbfcb71b0e7f1e"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"ca0e3dea87604e6a95a3bf5695c5bcab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德Q1净利润及明星减肥药销量均高于预期，上调2026年业绩展望","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","NVOX","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144481720","title":"诺和诺德Ozempic口服药即将于5月4日起在美国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1144481720","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144481720?lang=zh_cn&edition=full","pubTime":"2026-05-01 20:30","pubTimestamp":1777638622,"startTime":"0","endTime":"0","summary":"5月1日，诺和诺德公司正在美国将一种现有的、不太受欢迎的糖尿病药片重新命名为 Ozempic，以期利用全球最畅销药物之一的品牌知名度。今年 2 月，当 Ozempic 药丸获得美国食品药品监督管理局批准时，诺和诺德表示，在美国逐步淘汰 Rybelsus 品牌是合理的。此次推出口服药片，标志着诺和诺德公司旗下的Ozempic产品线不再局限于注射剂。诺和诺德表示，对于大多数有医保的患者来说，Ozempic口服药片的价格可能低至25美元，可供三个月使用。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9ec680a2539a9ae8f051490080e2eee7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德Ozempic口服药即将于5月4日起在美国上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","NVO","NVOH"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2631651431","title":"美国FDA提议将诺和诺德、礼来减肥药移出批量配药清单，两家药企迎来利好","url":"https://stock-news.laohu8.com/highlight/detail?id=2631651431","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631651431?lang=zh_cn&edition=full","pubTime":"2026-04-30 23:36","pubTimestamp":1777563360,"startTime":"0","endTime":"0","summary":"　　美国食品药品监督管理局提议，将诺和诺德与礼来旗下爆款肥胖及糖尿病药物的活性成分，从外包机构可用于批量配药的药品目录中剔除。　　若该提案最终落地，此举将限制这类药物的大规模仿制调配生产；除非相关药品被列入 FDA药品短缺清单，否则不得批量配药。　　FDA 在公告中称，目前不存在临床必要性，需要外包机构使用原料药批量调配上述药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-30/doc-inhwhzrz7241664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","LU0256863811.USD","LU0061475181.USD","IE0004445015.USD","LU2237443895.HKD","LU0964807845.USD","ELIL","LU1267930730.SGD","LU2491049909.HKD","LU1868837300.USD","LU0820561909.HKD","NVOX","LU0943347566.SGD","BK4007","LU2028103732.USD","SG9999014906.USD","LU0210536198.USD","LU2357305700.SGD","LU1057294990.SGD","LU2471134879.HKD","LU0354030438.USD","IE0004445239.USD","LU0198837287.USD","LU1629891620.HKD","LU2491050071.SGD","BK4532","LU2602419157.SGD","LU1868836914.USD","LLII","LU2063271972.USD","BK4585","LU0203201768.USD","LU2023251221.USD","IE00B7KXQ091.USD","BK4533","LU2417539215.USD","BK4516","LU0385154629.USD","LU0823416689.USD","LU0787776722.HKD","IE00B2B36J28.USD","LU2456880835.USD","LU0786609619.USD","LU1064131342.USD","LU1291159041.SGD","IE0009355771.USD","LU1868836591.USD","LU0097036916.USD","LU2237443549.SGD","IE00BWXC8680.SGD","LU0109394709.USD","LU0320765992.SGD","LLY","IE00BFSS8Q28.SGD","LU2089283258.USD","LU2023250504.SGD","LU1323610961.USD","LU2087625088.SGD","SG9999018865.SGD","LU2324357040.USD","LU2168564495.EUR","IE00BKPKM429.USD","LU1023059063.AUD","LU2361044949.HKD","IE0005OL40V9.USD","SG9999017495.SGD","LU1366192091.USD","IE00B1XK9C88.USD","LU1061106388.HKD","LU1623119135.USD","LU2089984988.USD","LU1145028129.USD","ELIS","LU2237443978.SGD","SGXZ31699556.SGD","SG9999015986.USD","LU0238689110.USD","LU2211815571.USD","LU2461242641.AUD","LU0471298777.SGD","IE00B775H168.HKD","LU1712237335.SGD","IE00B1BXHZ80.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0672654240.SGD","IE00BFSS7M15.SGD","LU2237443622.USD","IE00BK4W5L77.USD","LU1814569148.SGD","LLYX","LU2236285917.USD","LU2168564222.USD","SG9999001176.USD","LU1069344957.HKD","LU1551013425.SGD","LU0354030511.USD","LU2468319806.SGD","LU0683600562.USD","LU1548497426.USD","LU2168563687.JPY","LU0225283273.USD","LU0708995401.HKD","LU1720051108.HKD","LU2264538146.SGD","LU1232071149.USD","LU2023250330.USD","LU2471134952.CNY","LU1917777945.USD","LU2265009873.SGD","IE00BN29S564.USD","LU2746668461.USD","IE0001KFT4U8.USD","LU1093756325.SGD","LU0203202063.USD","LU2552382132.HKD","IE00BKDWB100.SGD","LU0094547139.USD","LU1988902786.USD","LU1127390331.HKD","BK4588","LLYZ","LU2111349929.HKD","LU0122379950.USD","LU1551013342.USD","LU0640476718.USD","LU2112291526.USD","LU2360106947.USD","LU0289739699.SGD","LU2168564149.EUR","LU0456855351.SGD","LU0234572021.USD","LU0109391861.USD","LU0353189763.USD","LU1280957306.USD","LU0466842654.USD","LU0432979614.USD","LU2756315318.SGD","LU1720051017.SGD","LU2756315664.SGD","SG9999015945.SGD","LU0133085943.USD","LU0689472784.USD","LU0266013472.USD","LU0079474960.USD","LU0882574055.USD","LU2750360641.GBP","LU0114720955.EUR","LU2471134796.USD","LU2552382058.USD","LU1983299246.USD","LU0820562030.AUD","SG9999014880.SGD","LU2896262040.SGD","SG9999018857.SGD","LU2271345857.HKD","LU2462157665.USD","LU2552382215.SGD","SGXZ57979304.SGD","IE00BJT1NW94.SGD","LU1093756168.USD","LU0353189680.USD","LU1868837136.USD","LU1868836757.USD","LU2361045086.USD","SG9999001176.SGD","SG9999015952.SGD","LU0323591593.USD","LU0823434740.USD","LU2746668974.SGD","LU2108987350.USD","LU1974910355.USD","LU2237443382.USD","LU2491050154.USD","LU0471298694.HKD","SGXZ81514606.USD","LU2471134523.USD","LU2168564065.EUR","NVO","SG9999014898.SGD","BK4599","IE00B4JS1V06.HKD","SGXZ99366536.SGD","LU2361044865.SGD","LU2213496289.HKD","SG9999015978.USD","LU0320765059.SGD","LU0882574139.USD","LU0096364046.USD","LU0158827781.USD","LU2237438978.USD","IE0002141913.USD","LU2106854487.HKD","IE00BZ1G4Q59.USD","LU0823434583.USD","GB00BDT5M118.USD","SGXZ51526630.SGD","LU0889565916.HKD","IE00BJLML261.HKD","LU0158827948.USD","IE00BFTCPJ56.SGD","LU0820561818.USD","SG9999014914.USD","LU0417517546.SGD","LU0006306889.USD","LU0316494557.USD","LU0154236417.USD","NVOH","LU1035775433.USD","IE00BJJMRX11.SGD","LU0106261372.USD","LU1804176565.USD","LU2089284900.SGD","LU2237443465.HKD","SG9999013999.USD","IE00BJJMRY28.SGD","LU0256863902.USD","BK4534","LU1989771016.USD","IE00BK4W5M84.HKD","BK4581","LU2750360997.AUD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.1484},{"period":"3month","weight":-0.0519},{"period":"6month","weight":-0.0561},{"period":"1year","weight":-0.3405},{"period":"ytd","weight":-0.1164}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.444444,"avgChangeRate":0.006415},{"month":4,"riseRate":0.622222,"avgChangeRate":0.018023},{"month":5,"riseRate":0.565217,"avgChangeRate":0.019393},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}